Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

AI BRIEFING

• ⬤ Theolytics announces first patient dosed in Phase 1 trial for ovarian cancer treatment
• ⬤ THEO-260, a novel oncolytic immunotherapy, targets Platinum-Resistant Ovarian Cancer
• ⬤ US-based Phase 1 trial evaluates intraperitoneal administration of THEO-260